PTC Inc.
Oct 10, 2017

Terumo BCT Selects Windchill Quality Management to Enhance Global Quality Processes

NEEDHAM, Mass.--(BUSINESS WIRE)-- PTC (NASDAQ: PTC) today announced that Terumo¬†BCT has selected the Windchill® Quality Management solution to support the company's continuous improvement initiatives for quality systems and processes around the world.

Terumo BCT, a medical technology company, holds a global leadership position in blood component, therapeutic apheresis, and cellular technologies. The company is dedicated to improving the efficiency of blood and cellular therapies, along with clinical and patient outcomes.

Windchill Quality Management will support Terumo BCT's various quality systems and its mission to ultimately provide the highest level of value to its customers throughout the world. The software system will enable the company to track, analyze, and use essential inputs to continually improve product design, quality control, training, and supply chain issues.

Windchill Quality Management enables medical device manufacturers to address Product Lifecycle Management (PLM) and Quality Management System (QMS) functions in a single system. It includes best-practice configurations purpose-built for medical device manufacturers. The solution allows medical device makers to standardize on quality management best practices, reduce regulatory overhead, and share quality and engineering intelligence.

Terumo BCT chose Windchill based on the strength of its Quality Management System (QMS) and Document Control (DC) capabilities. With this unified solution, Terumo BCT can triage and adjudicate customer complaints to ensure that external sources for quality issues are accurately managed for rapid correction and prevention. The company also plans to deploy PTC's CAPA and Nonconformance (NC) Management modules as part of the integrated platform.

"With our long-standing commitment to provide continuous improvements that create quality that delights our customers, we needed a solution provider with a comprehensive offering, a scalable architecture, and a commitment to the medical device market - and we found all of that in PTC," stated Jayne Odom, VP Enterprise Portfolio Management, Terumo BCT.

To meet the FDA CfQ initiative, medical device companies need technology that enables industry best practices for Design Control, Document Control, Nonconformance Management (NC), Complaint Management (CEM), Corrective and Preventive Action (CAPA), Risk Management, Audit Management and Unique Device Identification (UDI). PTC's solution provides all of these capabilities in one platform and is harmonized for ISO 13485, FDA TPLC and 21 CFR Part 820 regulations. It provides medical manufacturing companies with proactive, high-quality and fully traceable product development processes. With pre-configured, out-of-the-box best practices designed for life sciences companies, PTC solutions enable companies to maximize patient safety and efficacy while following best practices for regulated life sciences environments.

"Today's medical device manufacturers face many complex challenges and are continuously improving processes and technology to foster proactive design-based quality management," said Kevin Wrenn, divisional general manager, PLM Segment, PTC. "We are pleased to be supporting Terumo BCT's ongoing mission to enhance quality processes so they can provide the highest level of value to their customers."

For more than twenty years, PTC has partnered with leading life sciences companies to advance the state of medical engineering. Today 27 of the top 30 medical device companies rely on PTC products to help engineer, manufacture, and service successful medical products.

Additional Resources

The announcement of a customer's selection of PTC software is not necessarily indicative of the timing of recognition of related revenue or the amount of revenue for any particular period or that any related applicable implementation and deployment activities are complete.

About Terumo BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

About PTC (NASDAQ: PTC)
PTC has the most robust Internet of Things technology in the world. In 1986 we revolutionized digital 3D design, and in 1998 were first to market with Internet-based PLM. Now our leading IoT and AR platform and field-proven solutions bring together the physical and digital worlds to reinvent the way you create, operate, and service products. With PTC, global manufacturers and an ecosystem of partners and developers can capitalize on the promise of the IoT today and drive the future of innovation.

PTC.com @PTC Blogs

PTC, Windchill, and the PTC logo are trademarks or registered trademarks of PTC Inc. or its subsidiaries in the United States and other countries.

PTC
Jack McAvoy, 781-370-6143
Corporate Communications
jmcavoy@ptc.com
or
Michelle Hopkins, 678-515-7651
mihopkins@ptc.com

Source: PTC

News Provided by Acquire Media